Rise and shine, another brand new day is here. Thanks to a sunny sky and some cool breezes, we are finding it easy enough to deflect the chaos and concern permeating the world around us. A few quizzical looks from our official mascot — a challenging, but fast-growing source of amusement — also helps. Meanwhile, the time has come for the usual rituals — firing up the coffee kettle and foraging for items of interest. Speaking of which, here are a few. Hope your day is productive and safe. And of course, do keep in touch. …

The Trump administration signed a $354 million four-year contract with Phlow, a new company in Richmond, Va., to make generic drugs and pharmaceutical ingredients needed to treat Covid-19, which are now made overseas, mostly in India and China, The New York Times says. The contract meshes President Trump’s “America First” promises with concerns that coronavirus treatments be made in the U.S. It may be extended for up to $812 million over 10 years, making it one of the largest awards by the Biomedical Advanced Research and Development Authority.

President Trump said he is taking hydroxychloroquine, a decades-old malaria drug, to protect against Covid-19, despite warnings from his own government that it should only be administered in a hospital or research setting due to potentially fatal side effects, the Associated Press informs us. Trump, who said he had been taking the drug for “about a week and a half,” has spent weeks pushing the tablet as a potential cure or prophylaxis for Covid-19 against the cautionary advice of many of his administration’s top medical professionals.

AstraZeneca (AZN) is in talks with international organizations and governments around the world to strike coronovirus vaccine-production deals similar to one it struck with the U.K. over the weekend, Reuters notes. The organizations include the Coalition for Epidemic Preparedness Innovations and the Global Alliance for Vaccines and Immunization. The deal announced on Sunday will see AstraZeneca manufacture up to 30 million doses by September as part of a commitment to deliver 100 million doses in total for people in the U.K.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy